Lumos Pharma Announced Oral Presentation Highlighting Data On 15 Subjects From OraGrowtH212 Trial Supportive Of Conclusions From Interim Data Analysis
Lumos Pharma, Inc. (NASDAQ: LUMO) announced today that additional data from its OraGrowtH212 trial was included in an oral presentation of interim results at the 2023 International Meeting of Pediatric Endocrinology (IMPE), held in Buenos Aires, Argentina, March 4-7, 2023.